The novel severe
acute respiratory syndrome coronavirus (SARS-CoV-2)
emerged at the end of 2019, resulting in the ongoing COVID-19 pandemic.
The high transmissibility of the virus and the substantial number
of asymptomatic individuals have led to an exponential rise in infections
worldwide, urgently requiring global containment strategies. Reverse
transcription-polymerase chain reaction is the gold standard for the
detection of SARS-CoV-2 infections. Antigen tests, targeting the spike
(S) or nucleocapsid (N) viral proteins, are considered as complementary
tools. Despite their shortcomings in terms of sensitivity and specificity,
antigen tests could be deployed for the detection of potentially contagious
individuals with high viral loads. In this work, we sought to develop
a sandwich aptamer-based assay for the detection of the S protein
of SARS-CoV-2. A detailed study on the binding properties of aptamers
to the receptor-binding domain of the S protein in search of aptamer
pairs forming a sandwich is presented. Screening of aptamer pairs
and optimization of assay conditions led to the development of a laboratory-based
sandwich assay able to detect 21 ng/mL (270 pM) of the protein with
negligible cross-reactivity with the other known human coronaviruses.
The detection of 375 pg of the protein in viral transport medium demonstrates
the compatibility of the assay with clinical specimens. Finally, successful
detection of the S antigen in nasopharyngeal swab samples collected
from suspected patients further establishes the suitability of the
assay for screening purposes as a complementary tool to assist in
the control of the pandemic.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.